

List of Study Group 2024-2025

2025

1. Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, Cheong JW, Ikezoe T, et al. A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia. *Int J Hematol.* 2025;121:56–67.
<https://link.springer.com/article/10.1007/s12185-024-03840-x>
2. Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, et al. A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes. *Int J Hematol.* 2025;121:68–78.
<https://link.springer.com/article/10.1007/s12185-024-03872-3>
3. Miyao K, Murata M, Nishida T, Ozawa Y, Uchida N, Fukuda T, et al. Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease. *Int J Hematol.* 2025;121:110–25.
<https://link.springer.com/article/10.1007/s12185-024-03871-4>
4. Muta T, Masamoto Y, Yamamoto G, Kurahashi S, Kameoka Y, Ota S, et al. Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study. *Int J Hematol.* 2025;121:161–73.
<https://link.springer.com/article/10.1007/s12185-024-03875-0>
5. Sakamoto Y, Ishida T, Masaki A, Murase T, Ohtsuka E, Takeshita M, et al. Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma. *Int J Hematol.* 2025;121:206–21.
<https://link.springer.com/article/10.1007/s12185-024-03880-3>

6. Ishida T, Kuroda Y, Matsue K, Komeno T, Ishiguro T, Ishikawa J, et al. A Phase 1/2 study of teclistamab, a humanized BCMA×CD3 bispecific Ab in Japanese patients with relapsed/refractory MM. *Int J Hematol.* 2025;121:222–31.
<https://link.springer.com/article/10.1007/s12185-024-03884-z>
7. Ono R, Sakamoto K, Doi T, Yanagisawa R, Morimoto A, Kanegane H, et al. Dexamethasone palmitate for children with Epstein-Barr virus associated hemophagocytic lymphohistiocytosis. *Int J Hematol.* 2025;121:252–6.
<https://link.springer.com/article/10.1007/s12185-024-03892-z>
8. Arai H, Hosono N, Chi S, Fukushima K, Ikeda D, Iyama S, et al. A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02. *Int J Hematol.* 2025;121:378–87.
<https://link.springer.com/article/10.1007/s12185-024-03895-w>
9. Toyosaki M, Machida S, Tomizawa D, Okada M, Sawa M, Ueda Y, et al. Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement. *Int J Hematol.* 2025;121:388–96.
<https://link.springer.com/article/10.1007/s12185-024-03882-1>
10. Izutsu K, Ishikawa T, Shimada K, Kubo K, Kondo T, Fujimoto K, et al. Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL. *Int J Hematol.* 2025;121: 483–93.
<https://link.springer.com/article/10.1007/s12185-025-03925-1>
11. Eguchi K, Ishimura M, Ohga S, Endo S, Saito S, Kamimura S, et al. Adjunctive effects of eltrombopag on immunosuppressive therapy for childhood aplastic anemia. *Int J Hematol.* 2025;121:533–42.
<https://link.springer.com/article/10.1007/s12185-024-03903-z>

12. Ng SC, Moon JH, Park SS, Koh Y, Lee JH, Eom HS, et al. Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma. *Int J Hematol.* 2025;121: 670–83.
<https://link.springer.com/article/10.1007/s12185-025-03927-z>
13. Hagino T, Ikegame K, Tanaka H, Kanda Y, Kaida K, Fukuda T, et al. Engraftment outcome of patients with anti-HLA antibodies in HLA-mismatched peripheral blood stem cell transplantation. *Int J Hematol.* 2025;121:848–56.
<https://link.springer.com/article/10.1007/s12185-025-03952-y>
14. Makishima H, Mikasa T, Isogaya K, Miyamoto T, Yamauchi T, Yokota A, et al. Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351. *Int J Hematol.* 2025;122:57–65.
<https://link.springer.com/article/10.1007/s12185-025-03956-8>
15. Goto T, Okamura H, Ikeda T, Mori Y, Shiratori S, Fujiwara S, et al. Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study. *Int J Hematol.* 2025;122:93–105.
<https://link.springer.com/article/10.1007/s12185-025-03955-9>
16. Yoshikawa T, Ishida H, Watanabe A, Yuza Y, Shima H, Ito M, et al. Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era. *Int J Hematol.* 2025;122:117–27.
<https://link.springer.com/article/10.1007/s12185-025-03953-x>
17. Asano T, Morimoto A, Nakazawa A, Ueda T, Ogawa C, Sakata N, et al. Retrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes. *Int J Hematol.* 2025;122:128–37.

<https://link.springer.com/article/10.1007/s12185-025-03962-w>

18. Shimomura M, Ashiarai M, Kato I, Kamiya T, Taketomi N, Akita T, et al. Effect of conditioning intensity on late complications in AYA who underwent allogeneic HCT during childhood. *Int J Hematol.* 2025;122:138–47.
<https://link.springer.com/article/10.1007/s12185-025-03961-x>
19. Koh K, Kosaka Y, Okamoto Y, Maeda N, Ogawa A, Kobayashi R, et al. Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia. *Int J Hematol.* 2025;122:284–94.
<https://link.springer.com/article/10.1007/s12185-025-03976-4>
20. Yamaguchi H, Iino M, Kowata S, Yamamoto R, Yamanouchi J, Imamura Y, et al. A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia. *Int J Hematol.* 2025;122:521–32.
<https://link.springer.com/article/10.1007/s12185-025-04001-4>
21. Shimomura Y, Terakura S, Matsuo K, Ito Y, Ichinohe T, Hashii Y, et al. Impact of center volume on acute graft versus host disease in allogeneic stem cell transplant recipients. *Int J Hematol.* 2025;122:559–71.
<https://link.springer.com/article/10.1007/s12185-025-04003-2>
22. Hirakawa T, Yabe H, Hino M, Doki N, Yoshihara S, Ota S, et al. Safety of hematopoietic stem cell donation from young related donors following the lowering of the age of legal adulthood in Japan. *Int J Hematol.* 2025;122: 572–82.
<https://link.springer.com/article/10.1007/s12185-025-04007-y>
23. Yanagisawa R, Wakamatsu M, Tomomasa D, Sakamoto K, Ono R, Doi T, et al. Whole-genome sequencing reveals genetic

backgrounds in Japanese patients with hemophagocytic lymphohistiocytosis treated with the HLH-2004 protocol. *Int J Hematol.* 2025;122:583–9.

<https://link.springer.com/article/10.1007/s12185-025-04000-5>

24. Sakamoto K, Miyamoto S, Imai K, Sato M, Koh K, Koike T, et al. Hematopoietic cell transplantation in pediatric EB virus-associated hemophagocytic lymphohistiocytosis. *Int J Hematol.* 2025;122:598–604.

<https://link.springer.com/article/10.1007/s12185-025-04005-0>

25. Takahashi N, Kikushige Y, Nakamae H, Goto T, Tomita A, Ichii M, et al. Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST. *Int J Hematol.* 2025;122:647–59.

<https://link.springer.com/article/10.1007/s12185-025-04014-z>

26. Tsutsumi I, Yamamoto M, Fujio T, Kosugi N, Oshikawa G, Yamamoto K, et al. A phase 2 trial of VRD induction for transplant-eligible Japanese patients with newly diagnosed multiple myeloma. *Int J Hematol.* 2025;122:679–88.

<https://link.springer.com/article/10.1007/s12185-025-04010-3>

27. Katayama S, Moriya K, Imamura T, Tamefusa K, Sakaguchi K, Ishihara T, et al. Outcome of chemotherapy dose reduction in overweight Japanese children with acute lymphoblastic leukemia. *Int J Hematol.* 2025.

<https://link.springer.com/article/10.1007/s12185-025-04103-z>

28. Takahashi H, Tanaka S, Yuza Y, Iijima-Yamashita Y, Hasegawa D, Moritake H, et al. Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study. *Int J Hematol.* 2025.

<https://link.springer.com/article/10.1007/s12185-025-04060-7>

29. Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, et al. Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04058-1>
30. Tokuhira M, Nakayama H, Toyama K, Takano M, Iriyama N, Takahata A, et al. Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04069-y>
31. Imanaka R, Numata H, Katsuoka Y, Uoshima N, Hara S, Ando J, et al. Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study). *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04093-y>
32. Mori Y, Kohno K, Ueno T, Odawara J, Kawano N, Nagafuji K, et al. Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04124-8>
33. Iriyama N, Nakayama H, Nakagawa M, Takahata A, Sato E, Takano M, et al. Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04100-2>

34. Satake A, Nagate Y, Miyawaki K, Fujiwara Y, Ota S, Muta T, et al. Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR). *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04122-w>
35. Izutsu K, Watanabe M, Toubai T, Tsukamoto T, Maruyama D, Kumode T, et al. Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04095-w>
36. Takizawa J, Yoshida I, Ogawa Y, Toubai T, Kusumoto S, Watanabe M, et al. A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04114-w>
37. Suzuki K, Takaku T, Watanabe N, Iriyama N, Iwanaga E, Kimura Y, et al. Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04132-8>
38. Noguchi Y, Mori T, Onishi Y, Nakamura Y, Kanaya M, Ito S, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for acquired pure red cell aplasia. *Int J Hematol.* 2025.
<https://link.springer.com/article/10.1007/s12185-025-04137-3>

*****2024*****

1. Kashiwagi H, Kuwana M, Murata M, Shimada N, Takafuta T, Yamanouchi J, et al. Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition. *Int J Hematol.* 2024;119:1–13.

<https://link.springer.com/article/10.1007/s12185-023-03672-1>

2. Nogami K, Fujii T, Sawada A, Nagao A, Nagae C, Nojima M, et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. *Int J Hematol.* 2024;119:14–23.

<https://link.springer.com/article/10.1007/s12185-023-03679-8>

3. Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, et al. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). *Int J Hematol.* 2024;119:24–38.

<https://link.springer.com/article/10.1007/s12185-023-03677-w>

4. Onishi A, Matsumura-Kimoto Y, Mizutani S, Isa R, Fujino T, Tsukamoto T, et al. Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma. *Int J Hematol.* 2024;119:50–61.

<https://link.springer.com/article/10.1007/s12185-023-03680-1>

5. Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, et al. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). *Int J Hematol.* 2024;119:130–45.

<https://link.springer.com/article/10.1007/s12185-023-03686-9>

6. Makita S, Ota S, Mishima Y, Usuki K, Ennishi D, Yanada M, et al. Japanese phase Ib study of the oral PI3K- δ and - γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. *Int J Hematol.* 2024;119:156–63.

<https://link.springer.com/article/10.1007/s12185-023-03689-6>

7. Fukunaga K, Ikegame K, Nakamae H, Doki N, Fukuda T, Kondo Y, et al. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis. *Int J Hematol.* 2024;119:173–82.
<https://link.springer.com/article/10.1007/s12185-023-03693-w>
8. Minakata D, Uchida T, Nakano A, Takase K, Tsukada N, Kosugi H, et al. Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study. *Int J Hematol.* 2024;119:183–95.
<https://link.springer.com/article/10.1007/s12185-023-03685-w>
9. Kumano O, Suzuki S, Yamazaki M, An Y, Yasaka M, Ieko M, et al. Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants. *Int J Hematol.* 2024;119:407–15.
<https://link.springer.com/article/10.1007/s12185-024-03712-4>
10. Ogata M, Oshima K, Takano K, Kawano R, Ueda Y, Imamura T, et al. Effects of human herpesvirus 6B reactivation on cognitive function in cord blood transplant recipients: a prospective multicenter study. *Int J Hematol.* 2024;119:432–41.
<https://link.springer.com/article/10.1007/s12185-024-03714-2>
11. Ueki H, Ogawa C, Goto H, Nishi M, Yamanaka J, Mochizuki S, et al. TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia. *Int J Hematol.* 2024;119:450–8.
<https://link.springer.com/article/10.1007/s12185-024-03710-6>
12. Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, et al. A phase 1/2 study of NS-87/CPX-351 (cytarabine and

daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. *Int J Hematol.* 2024;119:647–59.

<https://link.springer.com/article/10.1007/s12185-024-03733-z>

13. Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, et al. End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial. *Int J Hematol.* 2024;119: 677–85.
<https://link.springer.com/article/10.1007/s12185-024-03738-8>
14. Ide D, Fujino T, Kobayashi T, Egashira A, Miyashita A, Mizuhara K, et al. Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio. *Int J Hematol.* 2024;119:697–706.
<https://link.springer.com/article/10.1007/s12185-024-03750-y>
15. Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, et al. Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016–2021). *Int J Hematol.* 2024;119:707–21.
<https://link.springer.com/article/10.1007/s12185-024-03754-8>
16. Sano H, Fukushima K, Yano M, Osone S, Kato Y, Hasegawa D, et al. Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study. *Int J Hematol.* 2024;119:745–54.
<https://link.springer.com/article/10.1007/s12185-024-03745-9>
17. Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, et al. Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study. *Int J*

Hematol. 2024;120:60–70.

<https://link.springer.com/article/10.1007/s12185-024-03758-4>

18. Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, et al. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. *Int J Hematol.* 2024;120:106–16.
<https://link.springer.com/article/10.1007/s12185-024-03772-6>
19. Tomomasa D, Tanita K, Hiruma Y, Hoshino A, Kudo K, Azumi S, et al. Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH. *Int J Hematol.* 2024;120:241–51.
<https://link.springer.com/article/10.1007/s12185-024-03786-0>
20. Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCSEMBL Study. *Int J Hematol.* 2024;120:305–13.
<https://link.springer.com/article/10.1007/s12185-024-03805-0>
21. Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, et al. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial. *Int J Hematol.* 2024;120:314–24.
<https://link.springer.com/article/10.1007/s12185-024-03822-z>
22. Ohwada C, Sakaida E, Takeda Y, Doki N, Igarashi A, Onizuka M, et al. Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort. *Int J Hematol.* 2024;120:347–55.

<https://link.springer.com/article/10.1007/s12185-024-03813-0>

23. Ureshino H, Takahashi N, Ikezoe T, Kameoka Y, Kimura S, et al. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial). *Int J Hematol.* 2024;120:492–500.

<https://link.springer.com/article/10.1007/s12185-024-03830-z>

24. Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, et al. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. *Int J Hematol.* 2024;120: 621–30.

<https://link.springer.com/article/10.1007/s12185-024-03834-9>

25. Goto H, Kada A, Ogawa C, Nishiuchi R, Yamanaka J, Iguchi A, et al. Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group. *Int J Hematol.* 2024;120:631–8.

<https://link.springer.com/article/10.1007/s12185-024-03838-5>

26. Miyakawa Y, Sato E, Ogawa Y, Nishimura J, Nishimi M, Kawaguchi O, et al. Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease. *Int J Hematol.* 2024;120:656–64.

<https://link.springer.com/article/10.1007/s12185-024-03842-9>

27. Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera *Int J Hematol.* 2024;120:675–83.

<https://link.springer.com/article/10.1007/s12185-024-03846-5>

28. Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T, et al. Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan. *Int J Hematol.* 2024;120:684–93.
<https://link.springer.com/article/10.1007/s12185-024-03862-5>
29. Shiratori S, Fukushima K, Onishi Y, Doki N, Goto T, Okada M, et al. Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study. *Int J Hematol.* 2024;120:705–16.
<https://link.springer.com/article/10.1007/s12185-024-03850-9>
30. Shimonodan H, Sakaguchi K, Ishihara T, Okamoto Y, Nishikawa T, Keino D, et al. Silent inactivation of asparaginase in Japan: results of the prospective ALL-ASP19 trial. *Int J Hematol.* 2024;120:725–34.
<https://link.springer.com/article/10.1007/s12185-024-03856-3>